RU2016117290A - Композиции, содержащие s-аденозилметионин и сложный эфир галловой кислоты - Google Patents
Композиции, содержащие s-аденозилметионин и сложный эфир галловой кислоты Download PDFInfo
- Publication number
- RU2016117290A RU2016117290A RU2016117290A RU2016117290A RU2016117290A RU 2016117290 A RU2016117290 A RU 2016117290A RU 2016117290 A RU2016117290 A RU 2016117290A RU 2016117290 A RU2016117290 A RU 2016117290A RU 2016117290 A RU2016117290 A RU 2016117290A
- Authority
- RU
- Russia
- Prior art keywords
- gallate
- gallic acid
- disease
- same
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Addiction (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- AIDS & HIV (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
Claims (7)
1. Композиция, содержащая сложный эфир галловой кислоты, выбранный из группы, состоящей из этилгаллата, пропилгаллата, изопропилгаллата, бутилгаллата, изобутилгаллата, амилгаллата, изоамилгаллата, гексилгаллата, изогексилгаллата, гептилгаллата, изогептилгаллата, октилгаллата, изооктилгаллата, нонилгаллата, изононилгаллата, децил изодецил, ундецил галлата, изоундецилгаллата, додецилгаллата (лаурилгаллата), изододецилгаллата, тридецилгаллата, изотридецил, тетрадецил галлата, изотетрадецил галлата, пентадецилгаллата, изопентадецилгаллата, гексадецилгаллата (цетилгаллата), изогексадецилгаллата, гептадецилгаллата, изогептадецилгаллата, октадецилгаллата, изоктадецилгаллата, цис-9-гексадеценил(пальмитолеил)галлата, цис-9-октадеценил(олеил)галлата, цис,цис-9,12 октадекадиенил(линолеил)галлата, транс,транс-9,12-октадекадиенил(линолелаидил)галлата, цис,цис,цис-9,12,15-октадекатриенил(линоленил)галлата, транс,транс,транс-9,12,15-октадекатриенил(линоленлаидил)галлата, цис,цис,цис-6,9,12-октадекатриенил(гамма-линоленил)галлата, транс-9-октадеценил(элаидил)галлата или транс-9-гексадеценил(пальмителаидил)галлата, 2-этилгексилгаллата, 2-гидроксиэтилгаллата, 6-O-галлоилглюкозы, гамамелитаннина, метоксиэтоксиэтоксиэтил-м-дигаллата, теафлавина моногаллата А и В, и теафлавина дигаллата, для (а) увеличения уровней SAMe в плазме крови субъекта, и/или (b) увеличения абсорбции SAMe через слизистую стенку или эпителиальные клетки кишечника, причем указанная композиция дополнительно содержит SAMe или вводится субъекту в комбинации с SAMe.
2. Высоко биодоступная композиция, содержащая экзогенный S-аденозилметионин и по меньшей мере один сложный эфир галловой кислоты, причем указанная композиция при введении выбранной группе субъектов обеспечивает у данной выбранной группы субъектов среднюю максимальную концентрацию SAMe в плазме крови (среднюю Сmax), составляющую по меньшей мере примерно 120 нг/мл на каждые 100 мг иона SAMe.
3. Способ лечения или предотвращения и/или профилактики у субъекта заболевания или расстройства, выбранного из группы, состоящей из, но не ограничиваясь указанными, душевного или психического расстройства (например, психотических/настроенческих или непсихотических душевных расстройств, примерами которых являются депрессия и расстройства, связанные с приемом различных веществ, соответственно), заболеваний/расстройств нервной системы (например, заболевания центральной нервной системы, примером которого является болезнь Алыдгеймера), других неврологических заболеваний/расстройств (например, головных болей и расстройств сна), состояний, связанных с повреждением центральной нервной системы, заболеваний/расстройств печени (например, алкогольной болезни печени), рака (например, солидных видов рака и раковых заболеваний крови), суставных заболеваний/расстройств (например, артрита), воспалительного заболевания/расстройства (например, неспецифического язвенного колита), аутоиммунного заболевания/расстройства (например, системной красной волчанки и ревматоидного артрита), дегенеративного заболевания/расстройства (например, амиотрофического латерального склероза), заболевания/расстройства мягких тканей (например, фибромиалгии), болевого заболевания/расстройства, генетического расстройства, связанного с гипер- или гипометилированием, желудочно-кишечного заболевания/расстройства, болезни Леши-Нихана и расстройства, полностью или частично вызванного окислительным или свободно-радикальным повреждением, причем способ включает введение композиции, содержащей SAMe и один или большее количество сложных эфиров галловой кислоты, так что указанное заболевание лечится или предотвращается.
4. Способ улучшения фармакокинетических параметров экзогенного SAMe, введенного субъекту, включающий введение субъекту непарентеральной композиции, содержащей по меньшей мере одну физиологически эффективную дозу SAMe в комбинации с по меньшей мере одни сложным эфиром галловой кислоты, выбранным для улучшения фармакокинетических параметров указанного SAMe в субъекте, причем указанные фармакокинетические параметры измеряются у субъекта одним показателем из Cmax, AUC, и их комбинаций по сравнению с контрольной группой, которой вводили тот же или похожий состав SAMe, не содержащий сложный эфир галловой кислоты.
5. Композиция в форме пероральной дозированной формы для лечения заболеваний и/или расстройств, которые можно лечить при помощи S-аденозилметионина, причем композиция содержит экзогенный S-аденозилметионин и по меньшей мере один сложный эфир галловой кислоты, причем указанный сложный эфир галловой кислоты выбран из группы, состоящей из этилгаллата, изоамилгаллата, пропилгаллата и октилгаллата, причем указанная композиция содержит от примерно 1 до примерно 400 мг указанного сложного эфира галловой кислоты.
6. Композиция по п. 5, содержащая от примерно 5 до примерно 200 мг сложного эфира галловой кислоты.
7. Композиция по п. 6, содержащая от примерно 5 до примерно 100 мг сложного эфира галловой кислоты.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261715138P | 2012-10-17 | 2012-10-17 | |
US61/715,138 | 2012-10-17 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015118235/15A Division RU2586300C1 (ru) | 2012-10-17 | 2013-10-16 | Композиции, содержащие s-аденозилметионин и сложный эфир галловой кислоты |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2016117290A true RU2016117290A (ru) | 2018-10-23 |
Family
ID=50487370
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016117290A RU2016117290A (ru) | 2012-10-17 | 2013-10-16 | Композиции, содержащие s-аденозилметионин и сложный эфир галловой кислоты |
RU2015118235/15A RU2586300C1 (ru) | 2012-10-17 | 2013-10-16 | Композиции, содержащие s-аденозилметионин и сложный эфир галловой кислоты |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015118235/15A RU2586300C1 (ru) | 2012-10-17 | 2013-10-16 | Композиции, содержащие s-аденозилметионин и сложный эфир галловой кислоты |
Country Status (15)
Country | Link |
---|---|
US (6) | US9801896B2 (ru) |
EP (2) | EP2753336B1 (ru) |
JP (2) | JP5877935B2 (ru) |
KR (2) | KR101748053B1 (ru) |
CN (2) | CN106074589A (ru) |
AU (1) | AU2013332209B2 (ru) |
CA (1) | CA2888302C (ru) |
DK (1) | DK2753336T3 (ru) |
ES (1) | ES2540581T3 (ru) |
HK (2) | HK1199836A1 (ru) |
IL (1) | IL243585A0 (ru) |
IN (1) | IN2015DN04151A (ru) |
RU (2) | RU2016117290A (ru) |
SG (1) | SG11201503048TA (ru) |
WO (1) | WO2014059522A1 (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2015DN04151A (ru) | 2012-10-17 | 2015-10-16 | Methylation Sciences Internat Srl | |
WO2015159155A2 (en) * | 2014-04-14 | 2015-10-22 | Methylation Sciences International Srl | Novel ademetionine formulations |
RU2587331C1 (ru) * | 2015-06-19 | 2016-06-20 | Общество с ограниченной ответственностью "Полигепазол" | Способ получения фармацевтической композиции адеметионина и его лекарственной формы |
CN105232515A (zh) * | 2015-10-10 | 2016-01-13 | 齐齐哈尔医学院 | 没食子酸乙酯用于制备治疗人结肠癌凋亡药物的应用 |
CN105476982A (zh) * | 2016-02-02 | 2016-04-13 | 张干 | 没食子酸的新用途 |
EP3243804B1 (en) | 2016-05-03 | 2020-07-15 | Heraeus Quartz North America LLC | Elongation method for producing an optical glass component |
CN108853085A (zh) * | 2017-05-15 | 2018-11-23 | 苏州凯祥生物科技有限公司 | 儿茶素类和表儿茶素类化合物用于上调MicroRNA-126表达水平的用途 |
CN111265509A (zh) * | 2020-02-19 | 2020-06-12 | 齐鲁工业大学 | 没食子酸衍生物防治动脉粥样硬化疾病的应用 |
CN114931571A (zh) * | 2022-03-30 | 2022-08-23 | 上海中医药大学附属曙光医院 | 没食子酸甲酯在制备骨关节炎治疗药物中的应用 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE37913B1 (en) | 1972-08-02 | 1977-11-09 | Bioresearch Sas | Salt of s-adenosyl-l-methionine |
IT1173992B (it) | 1984-05-16 | 1987-06-24 | Bioresearch Spa | Sali stabili della solfo-adenosil-l-metionina (same) particolarmente idonei per uso farmaceutico orale |
FR2623396B1 (fr) | 1987-11-25 | 1990-03-30 | Sanofi Sa | Utilisation de l'ademetionine contre le vieillissement de la peau |
GB8900812D0 (en) | 1989-01-14 | 1989-03-08 | Univ Manchester | Pharmaceutical method and compositions |
JPH05271067A (ja) | 1992-03-24 | 1993-10-19 | Takeda Chem Ind Ltd | 線維化抑制剤 |
RU2018314C1 (ru) | 1993-07-15 | 1994-08-30 | Приморское научное медико-техническое общество | Средство для лечения экземы |
DE19631085A1 (de) | 1996-08-01 | 1998-02-05 | Basf Ag | Verwendung von (Meth)acrylsäure-Maleinsäure-Copolymeren zur Verbesserung der Permeabilität der Schleimhaut |
US5962522A (en) | 1997-09-05 | 1999-10-05 | Avmax, Inc. | Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds |
US6180666B1 (en) | 1997-09-05 | 2001-01-30 | Anmax, Inc. | Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds |
US7906153B2 (en) | 1998-04-08 | 2011-03-15 | Theta Biomedical Consulting & Development Co., Inc. | Anti-inflammatory compositions for treating multiple sclerosis |
FI113942B (fi) | 2000-08-18 | 2004-07-15 | Control Ox Oy | Kasviperäisten fenolisten yhdisteiden käyttö valmistettaessa klamydiainfektion hoidossa ja ennaltaehkäisyssä käyttökelpoista farmaseuttista valmistetta, terveyteen myönteisesti vaikuttavaa ravintoainekoostumusta tai koostumusta lisättäväksi tällaisiin elintarvikkeisiin |
GB2368792A (en) | 2000-10-06 | 2002-05-15 | Roger Randal Charles New | Absorption enhancers |
US6759395B2 (en) | 2000-12-18 | 2004-07-06 | Orchid Chemicals & Pharmaceuticals, Ltd. | Soft-gelatin capsule comprising S-adenosylmethionine and a method for producing the same |
GB0308732D0 (en) | 2003-04-15 | 2003-05-21 | Axcess Ltd | Absorption enhancers |
GB0308734D0 (en) | 2003-04-15 | 2003-05-21 | Axcess Ltd | Uptake of macromolecules |
US8263574B2 (en) | 2004-09-29 | 2012-09-11 | James L. Schaller, P.A. | Topical formulations for the treatment of depression with S adenosyl methionine |
GB0603252D0 (en) | 2006-02-17 | 2006-03-29 | Axcess Ltd | Dissolution aids for oral peptide delivery |
US20070265211A1 (en) * | 2006-05-12 | 2007-11-15 | Matthias Rath | Novel composition and method effective in inhibiting the atherogenic process |
US20100056627A1 (en) | 2006-12-28 | 2010-03-04 | Tomihiko Higuchi | Pharmaceutical compositions of alkyl gallates |
US20090197824A1 (en) | 2008-01-31 | 2009-08-06 | Methylation Sciences International Srl | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
US20090088404A1 (en) | 2007-01-31 | 2009-04-02 | Methylation Sciences International Srl | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
US20080206333A1 (en) | 2007-01-31 | 2008-08-28 | Methylation Sciences International Srl | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
CN101012336A (zh) * | 2007-01-31 | 2007-08-08 | 浙江大学 | 含植物油的高强度可降解谷类蛋白质塑料及其制备方法 |
WO2010012109A1 (en) | 2008-08-01 | 2010-02-04 | Volkovs | System and method for the calculation of a polynomial-based hash function and the erindale-plus hashing algorithm |
WO2012012902A1 (en) * | 2010-07-28 | 2012-02-02 | Msi Methylation Sciences Inc. | S-adenosylmethionine formulations with enhanced bioavailability |
US20110027342A1 (en) | 2009-07-28 | 2011-02-03 | Msi Methylation Sciences, Inc. | S-adenosylmethionine formulations with enhanced bioavailability |
US8329208B2 (en) | 2009-07-28 | 2012-12-11 | Methylation Sciences International Srl | Pharmacokinetics of S-adenosylmethionine formulations |
WO2012170488A1 (en) | 2011-06-07 | 2012-12-13 | Zx Pharma, Llc | Multiparticulate s-adenosylmethionine compositions and related methods |
IN2015DN04151A (ru) | 2012-10-17 | 2015-10-16 | Methylation Sciences Internat Srl |
-
2013
- 2013-10-16 IN IN4151DEN2015 patent/IN2015DN04151A/en unknown
- 2013-10-16 AU AU2013332209A patent/AU2013332209B2/en not_active Ceased
- 2013-10-16 US US14/436,418 patent/US9801896B2/en active Active
- 2013-10-16 EP EP20130834351 patent/EP2753336B1/en active Active
- 2013-10-16 SG SG11201503048TA patent/SG11201503048TA/en unknown
- 2013-10-16 WO PCT/CA2013/000876 patent/WO2014059522A1/en active Application Filing
- 2013-10-16 CA CA2888302A patent/CA2888302C/en active Active
- 2013-10-16 RU RU2016117290A patent/RU2016117290A/ru not_active Application Discontinuation
- 2013-10-16 RU RU2015118235/15A patent/RU2586300C1/ru active
- 2013-10-16 CN CN201610230503.7A patent/CN106074589A/zh active Pending
- 2013-10-16 KR KR1020157012788A patent/KR101748053B1/ko active IP Right Grant
- 2013-10-16 JP JP2015537091A patent/JP5877935B2/ja not_active Expired - Fee Related
- 2013-10-16 DK DK13834351.2T patent/DK2753336T3/en active
- 2013-10-16 ES ES13834351.2T patent/ES2540581T3/es active Active
- 2013-10-16 CN CN201380054342.5A patent/CN104884067B/zh active Active
- 2013-10-16 EP EP15162054.9A patent/EP2949331A1/en not_active Withdrawn
- 2013-10-16 KR KR1020167020590A patent/KR20160094451A/ko not_active Application Discontinuation
-
2014
- 2014-04-07 US US14/247,061 patent/US8975238B2/en active Active
-
2015
- 2015-01-14 HK HK15100380.1A patent/HK1199836A1/zh not_active IP Right Cessation
- 2015-02-23 US US14/628,623 patent/US9925208B2/en active Active
- 2015-12-07 JP JP2015238622A patent/JP6280535B2/ja active Active
-
2016
- 2016-01-12 IL IL243585A patent/IL243585A0/en unknown
- 2016-05-24 HK HK16105924.2A patent/HK1217909A1/zh unknown
-
2018
- 2018-02-16 US US15/932,359 patent/US20190022119A1/en not_active Abandoned
-
2019
- 2019-12-26 US US16/727,610 patent/US20200129537A1/en not_active Abandoned
-
2022
- 2022-03-07 US US17/688,679 patent/US20220193107A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2016117290A (ru) | Композиции, содержащие s-аденозилметионин и сложный эфир галловой кислоты | |
US11413263B2 (en) | Reducing the risk of pathological effects of traumatic brain injury | |
JP2016074725A5 (ru) | ||
RU2017112149A (ru) | Комбинация омега-3 жирной кислоты и SGLT-2 ингибитора для лечения болезней печени | |
JP2019048843A5 (ru) | ||
RU2016129266A (ru) | Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания | |
US20100130608A1 (en) | Compositions and methods for reducing triglyceride levels | |
JP2013521310A5 (ru) | ||
US20070161705A1 (en) | Use of highly concentrated compositions of selected n-3 fatty acids for the treatment of central nervous system disturbances | |
NZ627238A (en) | Stable pharmaceutical composition comprising ethyl eicosapentaenoate | |
EP2720701B1 (en) | Therapeutic application of parenteral krill oil | |
RU2017125922A (ru) | Сложные эфиры для лечения офтальмологических воспалительных заболеваний | |
WO2011097273A1 (en) | Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl lcystenine | |
US20110086914A1 (en) | Methods for Treating Traumatic Brain Injury | |
JP2022537366A (ja) | Lpc-dha、lpc-epaなどの非経口リゾホスファチジルコリン製剤及びそれらの治療における使用 | |
KR20190022682A (ko) | Ards에 대한 리포뉴클레오티드-기반 요법 | |
RU2705991C2 (ru) | Применение тиаоксосоединений для уменьшения содержания аро с3 | |
US11123351B2 (en) | Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime | |
Scarsi et al. | The free fractions of circulating docosahexaenoic acid and eicosapentenoic acid as optimal end-point of measure in bioavailability studies on n-3 fatty acids | |
ES2922643T3 (es) | Adelmidrol pasa su uso en el tratamiento de enfermedades sensibles al agonismo específico del receptor PPAR-gamma | |
Fraser et al. | Icosabutate, a novel structurally engineered fatty-acid, exhibits potent anti-inflammatory and anti-fibrotic effects in a dietary mouse model resembling progressive human NASH | |
EP1960415B1 (en) | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same | |
US11510902B2 (en) | Method for preventing or treating non-alcoholic fatty liver disease by antrodins | |
KR20230128307A (ko) | 비알코올성 지방간염의 치료를 위한 산소-함유 구조적으로개선된 지방산을 포함하는 병용요법 | |
Todoran et al. | BIOAVAILABILITY OF VALPROATE SUPPOSITORIES FORMULATED FOR PAEDIATRIC USE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20190506 |